Synucleinopathy
Conditions
Interventions
Gold Standard:2015 MDS Parkinson's Disease Diagnostic Criteria, 2022 MDS MSA Diagnostic Criteria, 2017 4th Edition DLB Diagnostic Criteria, Polysomnography Monitoring, etc
Index test:Plasma cell-free RNA (cfRNA), skin phosphorylation a-synuclein deposition, cutaneous a-synuclein seeding activity.
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: Clinical Cohort of Synucleinopathies Inclusion criteria: Ages 40-75, diagnosed with probable PD according to the 2015 MDS criteria, probable MSA according to the 2022 MDS criteria, probable DLB according to the 2017 fourth edition clinical criteria, and non-synucleinopathy patients. All subjects must provide written informed consent. Early Risk Population Cohort for Synucleinopathies Inclusion criteria: Ages 30-75, patients diagnosed with idiopathic REM sleep behavior disorder (iRBD) through polysomnography, PAF patients meeting the autonomic failure criteria for probable MSA according to the 2022 MDS criteria, and healthy volunteers. All subjects must provide written informed consent.
Exclusion criteria
Exclusion criteria: ? Clinical cohort of synucleinopathies Exclusion criteria: Patients with other serious neurological diseases, significant cognitive impairment, or systemic diseases that may affect the study results. ? Early risk population cohort for synucleinopathies Exclusion criteria: Patients with other serious neurological diseases, significant cognitive impairment, or systemic diseases that may affect the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cell-free RNA ;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin phosphorylation a-synuclein pathology;Skin a-synuclein seeding activity; | — |
Countries
China
Contacts
Public ContactJing Yang
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed